Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73602249" target="_blank" >RIV/61989592:15110/20:73602249 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.futuremedicine.com/doi/abs/10.2217/fon-2020-0079" target="_blank" >https://www.futuremedicine.com/doi/abs/10.2217/fon-2020-0079</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2217/fon-2020-0079" target="_blank" >10.2217/fon-2020-0079</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma

Popis výsledku v původním jazyce

Sequential administration of single targeted agents has been challenged as the dominant treatment paradigm in patients with metastatic renal cell carcinoma by improved outcomes obtained with combination regimens based on immune checkpoint inhibitors. Most patients treated with sequential monotherapy eventually develop drug resistance and succumb to progressive disease, leading to the search for therapies that would overcome drug resistance and result in a more durable treatment response. Improved outcomes have been demonstrated in Phase 3 trials in comparison with sunitinib for the combinations of axitinib plus pembrolizumab, axitinib plus avelumab, bevacizumab plus atezolizumab and ipilimumab plus nivolumab. A statistically significant improvement of both progression-free and overall survival has been demonstrated for the axitinib plus pembrolizumab combination

Název v anglickém jazyce

Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma

Popis výsledku anglicky

Sequential administration of single targeted agents has been challenged as the dominant treatment paradigm in patients with metastatic renal cell carcinoma by improved outcomes obtained with combination regimens based on immune checkpoint inhibitors. Most patients treated with sequential monotherapy eventually develop drug resistance and succumb to progressive disease, leading to the search for therapies that would overcome drug resistance and result in a more durable treatment response. Improved outcomes have been demonstrated in Phase 3 trials in comparison with sunitinib for the combinations of axitinib plus pembrolizumab, axitinib plus avelumab, bevacizumab plus atezolizumab and ipilimumab plus nivolumab. A statistically significant improvement of both progression-free and overall survival has been demonstrated for the axitinib plus pembrolizumab combination

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Future Oncology

ISSN

1479-6694

e-ISSN

—

Svazek periodika

17

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

14

Strana od-do

241-254

Kód UT WoS článku

000575132400001

EID výsledku v databázi Scopus

2-s2.0-85100014930